Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

Elliott Vichinsky, MD, Victor R. Gordeuk, MD, Paul Telfer, DM, FRCP, Adlette Inati, MD FAAP, Margaret Tonda, PharmD, Sarah Gray, PhD, Irene Agodoa, MD, Kenneth I. Ataga, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140863

Published: 2020

Journal Articles

Pharmacokinetics of Ticagrelor in Infants and Toddlers Aged <24 Months with Sickle Cell Disease

Baba PD Inusa, MD, Adlette Inati, MD, Philip Maes, MD, Jessie Githanga, MBChB, MMed, Miguel R. Abboud, MD, Maurizio Miano, Elena Cela, Videlis Nduba, Mohammad Niazi, Magnus Åstrand, Kevin Persson, Anders Rikard Berggren, MD PhD, Glenn Carlson, MD

Blood (2019) 134 (Supplement_1): 1005.

https://doi.org/10.1182/blood-2019-129855

Published: 2019

Journal Articles

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Elliott P. Vichinsky, MD, Paul Telfer, DM, FRCP, Adlette Inati, MD, Margaret Tonda, PharmD, Barbara Tong, PhD, Irene Agodoa, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Kenneth I. Ataga, MD

Blood (2019) 134 (Supplement_1): 2313.

https://doi.org/10.1182/blood-2019-129026

Published: 2019

Journal Articles

Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01)

Bart J. Biemond, MD PhD, Anil Tombak, MD, Yurdanur Kilinc, MD, Murtadha Al-Khabori, MD, Miguel R. Abboud, MD, Mohammed Nafea, MD, Adlette Inati, MD, Yasser Ahmed Mohamed Soliman Wali, MD, Jens Kristensen, MD PhD, Ellen Donnelly, PhD, John Ohd, MD PhD

Blood (2019) 134 (Supplement_1): 614.

https://doi.org/10.1182/blood-2019-124653

Published: 2019

Journal Articles

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Kenneth I. Ataga, MD, Santosh L. Saraf, MD, Vimal K. Derebail, MD, Claire C. Sharpe, Adlette Inati, MD, Jeffrey D. Lebensburger, DO, MSPH, Laurie DeBonnett, MD, Shirong Zhang, Pablo Bartolucci, MD PhD

Blood (2019) 134 (Supplement_1): 1018.

https://doi.org/10.1182/blood-2019-124823

Published: 2019

Journal Articles

Sickle Cell Disease Burden in North Lebanon

Adlette Inati, MD, Chadi Al Alam, Cristel El Ojaimi, Taghrid Hamad, Hemanth Kanakamedala, Virginia Pilipovic, Ramzieh Sabah

Blood (2019) 134 (Supplement_1): 1022.

https://doi.org/10.1182/blood-2019-128311

Published: 2019

Journal Articles

Outcome Of Bone Marrow Transplantation In Lebanese Children With β-Thalassemia Major

Adlette Inati, MD, Javid Gaziev, MD, Hussein A Abbas, PhD, Serge Korjian, BSc, Yazan Daaboul, BSc, Mario Kahale, MD, Katia Paciaroni, MD, Gioia de Angelis, MD, Ali T Taher, MD, Therese Abi Nasr, MD, Suzan Koussa, MD, Guido Lucarelli, MD

Blood (2013) 122 (21): 5505.

https://doi.org/10.1182/blood.V122.21.5505.5505

Published: 2013

Journal Articles

Safety and Tolerability Of MP4CO: A Dose Escalation Study In Stable Patients With Sickle Cell Disease

Jo Howard, MB, BChir, MRCP, FRCPath, Swee Lay Thein, MBBS, DSc, Frederic Galacteros, MD PhD, Adlette Inati, MD, Marvin Reid, PhD, Peter E. Keipert, PhD, Tania N. Small, MD, Frank Booth, MA MSc BM BCh FACS

Blood (2013) 122 (21): 2205.

https://doi.org/10.1182/blood.V122.21.2205.2205

Published: 2013

Journal Articles

A Phase 2 Trial Of The Fetal Hemoglobin Inducer HQK-1001 (2,2-dimethylbutyrate, Sodium Salt) In Non-Transfusion-Dependent β-Thalassemia

Adlette Inati, MD, Mario Kahale, MD, Susan P Perrine, MD, Ali T Taher, MD, Suzanne Koussa, MD, Hussein A Abbas, PhD, Therese Abi Nasr, MD, Richard G. Ghalie, MD

Blood (2013) 122 (21): 2261.

https://doi.org/10.1182/blood.V122.21.2261.2261

Published: 2013

Journal Articles

A Multicenter Study On Hereditary Spherocytosis In Lebanon

Adlette Inati, MD, Peter Noun, MD, Nabil Kabbara, MD, Cynthia Salloum, MD, Michel Kmeid, MD, Maroun Sadek, MD, Mario Kahale, MD, Hussein A Abbas, PhD

Blood (2013) 122 (21): 4661.

https://doi.org/10.1182/blood.V122.21.4661.4661

Published: 2013

Journal Articles

A 2-Dose Schedule of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Given to Children with Sickle Cell Disease Previously Immunized with 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23): Results of a Phase 3 Study

Mariane De Montalembert, MD, Miguel R. Abboud, MD, Anne Fiquet, MD, Adlette Inati, MD, Jeffrey D. Lebensburger, DO, Normeen Kaddah, MD, Antonio Piga, MD, Baba Inusa, MD, Qin Jiang, MS, Lisa Pereira, BSc, Emilio A. Emini, PhD, William C. Gruber, MD, Alejandra Gurtman, MD, Daniel A. Scott, MD

Blood (2012) 120 (21): 3212.

https://doi.org/10.1182/blood.V120.21.3212.3212

Published: 2012

Journal Articles

A Randomized, Open-Label, Multicenter, Dose Escalation Study of HQK-1001 (2,2-Dimethylbutyrate, Sodium Salt) in Sickle Cell Disease

Abdullah Kutlar, MD, Marvin Reid, PhD, Ali T Taher, MD, Adlette Inati, MD, Miguel R. Abboud, MD, Amal El-Beshlawy, MD, George R. Buchanan, MD, Hedy Smith, MD PhD, Kenneth I. Ataga, MD, Nebu Koshy, MD, FACP, Lynne D Neumayr, MD, Punam Malik, M.D., Ofelia A. Alvarez, MD, Richard Ward, MBBS, MRCP, FRCPath, J Michael White, PhD, Elsa Johnson, MBA, Richard G. Ghalie, MD

Blood (2012) 120 (21): 998.

https://doi.org/10.1182/blood.V120.21.998.998

Published: 2012

Journal Articles

A Phase 2 Clinical Study of HQK-1001 (2,2-dimethylbutyrate, sodium salt), a Fetal Hemoglobin Inducer, in Patients with Sickle Cell Disease

Abdullah Kutlar, MD, Adlette Inati, MD, Ali T Taher, MD, Amal El-Beshlawy, MD, Marvin Reid, PhD, Miguel R. Abboud, MD, Hedy Smith, MD, PhD, Kenneth I. Ataga, MD, George R. Buchanan, MD, Punam Malik, MD, Nebu Koshy, MD, Lynne Neumayr, MD, Maria Aiello, MA, Elsa Johnson, MBA, J Michael White, PhD, Richard G. Ghalie, MD

Blood (2011) 118 (21): 1066.

https://doi.org/10.1182/blood.V118.21.1066.1066

Published: 2011

Journal Articles

Relationship Between Total Iron Removed by Phlebotomy and Iron Removed From the Liver in Pediatric Thalassemia Major Patients Following Curative Stem Cell Transplant

Adlette Inati, MD, Nada Sbeiti, MD, Ali T Taher, MD, Suzanne Koussa, MD, Timothy G St Pierre, PhD

Blood (2011) 118 (21): 5300.

https://doi.org/10.1182/blood.V118.21.5300.5300

Published: 2011

Journal Articles

1-Year Results From A Prospective Randomized Trial Comparing Phlebotomy with Deferasirox for the Treatment of Iron Overload in Pediatric Patients with Thalassemia Major Following Curative Stem Cell Transplantation

Adlette Inati, MD, Nada Sbeiti, MD, Evelyne Khoriaty, MD, M Domenica Cappellini, MD, Suzanne Koussa, MD, Therese Abi Nasr, MD, Khaled M Musallam, MD, Ali T Taher, MD

Blood (2011) 118 (21): 904.

https://doi.org/10.1182/blood.V118.21.904.904

Published: 2011

Journal Articles

Brain MRI Findings in Lebanese Sickle Cell Disease Patients.

Adlette Inati, MD, Youssef Rachkidi, MD, Ossama Jradi, MD, Rabih Wehbe, MD, Habib Moallem, PhD, Suzanne Koussa, MD, Ali Taher, MD

Blood (2007) 110 (11): 3794.

https://doi.org/10.1182/blood.V110.11.3794.3794

Published: 2007

Journal Articles

Effect of Zoledronic Acid on Bone Mineral Density in Thalassemia-Induced Osteoporosis: Results of a Phase II Clinical Trial.

Ali Taher, MD, Sami Azar, MD, Wael Shamseddeen, MD, MPH, Dany Habr, MD, Adlette Inati, MD, Suzane Koussa, MD, Rami Mahfouz, MD, Zaher Otrock, MD

Blood (2005) 106 (11): 3826.

https://doi.org/10.1182/blood.V106.11.3826.3826

Published: 2005

Journal Articles

Study on Intravenous Zoledronic Acid Treatment in Thalassemia-Induced Osteoporosis.

Zaher Otrock, MD, Sami Azar, MD, Adlette Inati, MD, Suzane Koussa, MD, Rami Mahfouz, MD, Ali Taher, MD.

Blood (2004) 104 (11): 3764.

https://doi.org/10.1182/blood.V104.11.3764.3764

Published: 2004

Journal Articles

Study on Hepatitis C Treatment Using Ribavirin and Pegylated Interferon in Thalassemia Patients (SCRIPT): One Year Report.

Adlette Inati, MD, Ala Sharara, MD, Sandy Ghorra, PharmD, Elie Aoun, MD, Marwan Taha, PharmD, Suzanne Koussa, MD, Ali Taher, MD.

Blood (2004) 104 (11): 3768.

https://doi.org/10.1182/blood.V104.11.3768.3768

Published: 2004

NARROW

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

Pharmacokinetics of Ticagrelor in Infants and Toddlers Aged <24 Months with Sickle Cell Disease

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01)

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Sickle Cell Disease Burden in North Lebanon

Outcome Of Bone Marrow Transplantation In Lebanese Children With β-Thalassemia Major

Safety and Tolerability Of MP4CO: A Dose Escalation Study In Stable Patients With Sickle Cell Disease

A Phase 2 Trial Of The Fetal Hemoglobin Inducer HQK-1001 (2,2-dimethylbutyrate, Sodium Salt) In Non-Transfusion-Dependent β-Thalassemia

A Multicenter Study On Hereditary Spherocytosis In Lebanon

A 2-Dose Schedule of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Given to Children with Sickle Cell Disease Previously Immunized with 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23): Results of a Phase 3 Study

A Randomized, Open-Label, Multicenter, Dose Escalation Study of HQK-1001 (2,2-Dimethylbutyrate, Sodium Salt) in Sickle Cell Disease

A Phase 2 Clinical Study of HQK-1001 (2,2-dimethylbutyrate, sodium salt), a Fetal Hemoglobin Inducer, in Patients with Sickle Cell Disease

Relationship Between Total Iron Removed by Phlebotomy and Iron Removed From the Liver in Pediatric Thalassemia Major Patients Following Curative Stem Cell Transplant

1-Year Results From A Prospective Randomized Trial Comparing Phlebotomy with Deferasirox for the Treatment of Iron Overload in Pediatric Patients with Thalassemia Major Following Curative Stem Cell Transplantation

Brain MRI Findings in Lebanese Sickle Cell Disease Patients.

Effect of Zoledronic Acid on Bone Mineral Density in Thalassemia-Induced Osteoporosis: Results of a Phase II Clinical Trial.

Study on Intravenous Zoledronic Acid Treatment in Thalassemia-Induced Osteoporosis.

Study on Hepatitis C Treatment Using Ribavirin and Pegylated Interferon in Thalassemia Patients (SCRIPT): One Year Report.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only